Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA
Myung-Soo Kang
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorHong-Joo Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorJae-Ho Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorJa-Lok Ku
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorKathreen P. Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorMichael J. Kelley
NCI-Navy Medical Oncology Branch, National Cancer Research, Naval Hospital Bethesda, MD
Search for more papers by this authorYong-Jin Won
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorSoo-Tae Kim
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Jae-Gahb Park
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-799 Korea. Fax: (82-2) 742-4727Search for more papers by this authorMyung-Soo Kang
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorHong-Joo Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorJae-Ho Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorJa-Lok Ku
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorKathreen P. Lee
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorMichael J. Kelley
NCI-Navy Medical Oncology Branch, National Cancer Research, Naval Hospital Bethesda, MD
Search for more papers by this authorYong-Jin Won
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorSoo-Tae Kim
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Jae-Gahb Park
Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-799 Korea. Fax: (82-2) 742-4727Search for more papers by this authorAbstract
It has been known that the incidence of p53 mutation is very rare in HBX-positive primary human hepatocellular carcinoma (HCC) tissues. The frequency of p53 mutation, however, in established cell lines with integrated HBV DNA and/or HBX has not been well studied. To know p53 mutational frequency, and to investigate whether the presence of HBX DNA sequence correlates with the absence of p53 mutation in the established HCC cell lines, we studied the p53 mutation and the presence of HBX sequence in 12 recently characterized HCC cell lines. As a result, all 12 (100%) lines showed mutation in the p53 gene. Three (25%) cell lines had transversion of codon 215 while no mutation of codon 249 was found. In contrast with previous reports, although HBX DNA was present in 11 cell lines, p53 mutation had occurred, indicating that the presence of HBX viral DNA does not correlate with a lack of p53 mutation in established HCC cell lines. Our results suggest that the frequency of p53 mutation is extremely high even in HBX DNA positive HCC cell lines. © 1996 Wiley-Liss, Inc.
References
- Bressac, B., Galvin, K. M., Liang, T. G., Isselbacher, K. J., Wands, J. and Ozturk, M., Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. nat. Acad. Sci. (Wash.), 87, 1973–1977 (1990).
- Bressac, B., Kew, M., Wands, J. and Ozturk, M., Selective G to T mutations of p53 gene in hepatocellular carcinoma from south Africa. Nature (Lond.), 350, 429–431 (1991).
- Cho, Y., Gorina, S., Jeffrey, P. D. and Palvetich, N. P., Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346–355 (1994).
- Di Bisceglie, A. M., Rustgi, V. K., Hoofnagle, J. H., Dusheiko, G. M. and Lotze, M. T., Hepatocellular carcinoma. Ann. int. Med., 108, 390–401 (1988).
- Diamantis, I. D., McGandy, C. E., Chen, T. J., Liag, Y. F., Gudat, F. and Bianchi, L., Hepatitis B X gene expression in hepatocellular carcinoma. J. Hepatol., 15, 400–403 (1992).
- Feitelson, M. A., Zhu, M., Duan, L. X. and London, W. T., Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8, 1109–1117 (1993).
- Fogh, J., Fogh, J. M. and Orfeo, T., One hundred and twenty-seven cultured human-tumor cell lines producing tumors in nude mouse. J. nat. Cancer Inst., 59, 221–225 (1977).
- Ganem, D., Varmus, H. E., The molecular biology of the hepatitis B viruses. Ann. Rev. Biochem., 56, 651–693 (1987).
- Greenblatt, M. S., Bennett, W. D., Hollstein, M. and Harris, C. C., Mutations in the p53 tumor suppressor gene: Clues to etiology and molecular pathogenesis. Cancer Res., 54, 4855–4878 (1994).
- Henkler, F., Waseen, N., Golding, M. H. C., Alison, M. R. and Koshy, R., Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res., 55, 6084–6091 (1995).
- Hollstein, M., Rice, C., Greenblatt, M. S., Soussi, T., Fuchs, T. and Sorlie, E., Database of p53 somatic mutations in human tumors and tumor cell lines, European Molecular Biology Laboratory, Heidelberg (1995).
- Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C., p53 mutations in human cancer. Science, 253, 49–53 (1991).
- Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J. and Harris, C. C., Mutational hotspot in the p53 gene in the human hepatocellular carcinoma. Nature (Lond.), 350, 427–428 (1991).
- Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsch, J. A., Sun, T. and Harris, C. C., p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis, 14, 987–992 (1993).
- Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J. and Hayashi, S., Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis, 14, 1085–1089 (1993).
- Kim, C. M., Koike, K., Saito, I., Miyamura, T. and Jay, O., HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (Lond.), 351, 317–320 (1991).
- Knowles, B., Howe, C. C. and Aden, D. P., Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209, 497–499 (1980).
- Lamb, P. and Crawford, L., Characterization of the human p53 gene. Mol. Cell Biol., 6, 1379–1385 (1986).
- Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D., D'Amico, D., Bonder, S., Oie, H. K., Linnoila, R., Mulshine, J., Minna, J. D. and Gazdar, A. F., p53 gene mutations in non small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7, 171–180 (1992).
- Moriarty, A. M., Alexander, H. and Lerner, R. A., Antibodies to peptides detect new hepatitis B antigen: Serological correlation with hepatocellular carcinoma. Science, 227, 429–433 (1985).
- Murakami, Y., Hayashi, K., Hirohashi, S. and Sekiya, T., Aberrations of the tumor suppressor p53 and retinoblastoma gene in human hepatocellular carcinomas. Cancer Res., 51, 520–5525 (1991a).
- Murakami, Y., Hayashi, K. and Sekiya, T., Detection of the p53 alleles and the gene transcript in human tumor cell lines by single strand conformation polymorphism analysis, Cancer Res., 51, 3356–3361 (1991b).
- Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D. W., Ikenega, M., Imamura, H. and Ishizaki, K., Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma, Cancer Res., 53, 368–372 (1993).
- Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. and Sekiya, T., Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. Proc. nat. Natl Acad. Sci. (Wash.), 86, 2766–2770 (1989).
- Ozturk, M. and 26 Others: p53 mutation in hepatocellular carcinoma after aflatoxin exposure, Lancet 338, 1356–1359 (1991).
- Park, J. G., Lee, S. K., Hong, I. K., Kim, H. S., Choe, K. J., Kim, W. H., Kim, Y. I., Tsuruo, T. and Gottesman, M. M., MDR1 gene expression: Its effects on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J. nat. Cancer Inst., 86, 700–705 (1994).
- Park, J. G. and 17 Others, Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer, 62, 276–282 (1995).
- Sambrook, J., Fritsch, E. F., Maniatis, T., Molecular cloning:a laboratory manual, ( 2nd ed.) Cold Spring Harbor Laboratory Press, NY (1989).
- Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Tereda, M. and Yokota, J., Alteration of p53 gene are common and critical events for the maintenance of malignant phenotypes in small cell lung cancer. Oncogene, 7, 451–457 (1992).
- Shin, H. R., HBV or HCV infection and risk of HCC in Korea. Proceeding of the Federation Meeting of Korean Basic Medical Scientist, p. 86 (1993).
- Shirakata, Y., Kawada, M., Fujiki, Y., Sano, H., Oda, M., Yaginuma, K., Kobayashi, M., and Koike, K., The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn. J. Cancer Res., 80, 617–621 (1898).
- Truant, R., Antunovic, J., Greenblatt, J., Prives, C., and Cromlish, J. A., Direct interaction of the hepatitis B virus HBX protein with p53 leads to inhibition by HBX of p53 response element directed transactivation. J. Virol., 69, 1851–1859 (1995).
- Unsal, H., Yakicier, C., Marcais, C., Kew, M., Volkmann, M., Zentgraft, H., Isselbacher, K. J. and Ozturk, M., Genetic heterogeneity of hepatocellular carcinoma. Proc. nat. Acad. Sci. (Wash.), 91, 822–826 (1994).
- Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. K., Gu, J.-R. and Harris, C. C., Hepatitis B virus X protein inhibits p53 sequencespecific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. nat. Acad. Sci. (Wash.), 91, 2230–2234 (1994).
- Weston, A., Ling-Cawley, H. M., Caporaso, N. E., Bowman, E. D., Hoover, R. N., Trump, B. F. and Harris, C. C., Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis, 15, 583–587 (1994).
- Weston, A., Perrin, L. S., Forrestor, K., Hoover, R. N., Trump, B. F., Harris, C. C. and Caporaso, N. E., Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol. Biomarkers Prev., 1, 481–483 (1992).
Citing Literature
